Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis

Published:2020-09-08 Issue:10 Volume:19 Page:1329-1338
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Massari Francesco¹,Mollica Veronica¹,Rizzo Alessandro¹,Cosmai Laura²,Rizzo Mimma³^ORCID,Porta Camillo⁴^ORCID

Affiliation:

1. Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2. Onco-Nephrology Outpatients Clinic, Division of Nephrology and Dialysis, ASST Santi Paolo e Carlo, San Paolo Hospital, Milan, Italy

3. Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy

4. Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1811226

Reference49 articles.

1. Cancer statistics, 2020

2. Renal cancer

3. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

4. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age

5. [cited 2020 Apr 14]. Available from: https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety;Urologic Oncology: Seminars and Original Investigations;2024-11

2. ITGB3 is a Novel Prognostic Biomarker and Correlates with Aberrant Methylation and Tumor Immunity in Clear Cell Renal Cell Carcinoma;Combinatorial Chemistry & High Throughput Screening;2024-08-12

3. Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids;Translational Oncology;2024-08

4. Exploring the prognostic implications of cuproptosis-associated alterations in clear cell renal cell carcinoma via in vitro experiments;Scientific Reports;2024-07-23

5. Exploring necrosis-associated mitochondrial gene signatures: revealing their role in prognosis and immunotherapy of renal clear cell carcinoma;Clinical and Experimental Medicine;2024-07-18